Atlas Trials

Shanghai Runshi Pharmaceutical Technology Co., Ltd

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Shanghai Runshi Pharmaceutical Technology Co., Ltd

RecordFirmDate
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas (NCT07613450)Shanghai Runshi Pharmaceutical Technology Co., Ltd2026-05-20
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma (NCT06739213)Shanghai Runshi Pharmaceutical Technology Co., Ltd2025-01-31
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. (NCT06682611)Shanghai Runshi Pharmaceutical Technology Co., Ltd2024-11-13
A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma (NCT06656091)Shanghai Runshi Pharmaceutical Technology Co., Ltd2024-10-31
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (NCT06577376)Shanghai Runshi Pharmaceutical Technology Co., Ltd2024-08-26
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors (NCT06132217)Shanghai Runshi Pharmaceutical Technology Co., Ltd2024-01-30
A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors (NCT05105464)Shanghai Runshi Pharmaceutical Technology Co., Ltd2021-06-25

Track Shanghai Runshi Pharmaceutical Technology Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.